Engineered interleukin-2 antagonists for the inhibition of regulatory T cells

Journal of Immunotherapy

Volumn 32, Issue 9, 2009, Pages 887-894

  Liu, David V ^a   Maier, Lisa M ^b   Hafler, David A ^b   Wittrup, K Dane ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antagonist engineering; Cytokine engineering; Interleukin 2; Regulatory T cells

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR GAMMA; STAT5 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IC 50; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; WILD TYPE;

CELL LINE; CELLS, CULTURED; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; JANUS KINASES; MUTANT PROTEINS; PHOSPHORYLATION; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 70350560651     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181b528da     Document Type: Article

References (49)

1. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+ CD25+ regulatory T cells. Semin Immunol. 2004;16:89-98.
2. Fehervari Z, Sakaguchi S. Development and function of CD25+ CD4+ regulatory T cells. Curr Opin Immunol. 2004; 16:203-208.
3. Marshall NA, Christie LE, Munro LR, et al. Immunosuppres-sive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
4. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+ CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61:4766-4772.
5. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adeno-carcinoma. J Immunol. 2002;169:2756-2761.
6. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-949.
7. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24:5373-5380.
8. Kobayashi N, Hiraoka N, Yamagumi W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007;13:902-911.
9. Mempel TR, Khazaie PK, Weninger W, et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity. 2006;25:129-141.
10. Chen ML, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA. 2005;102: 419-424.
11. Nishikawa H, Jager E, Ritter G, Old LJ, et al. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005;106:1008-1011.
12. Fontenot JD, Rudenski AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol. 2005;6: 331-337.
13. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
15. Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol. 2003;4:337-342.
16. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4+ CD25+ immunoregulatory T cells gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
17. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-309.
18. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27:145-159.
19. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006;177:84-91.
20. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
21. Litzinger MT, Fernando R, Curiel TJ, et al. IL-2 immunotoxin denileukin difitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007;110:3192-3201.
22. Curiel TJ, Barnett B, Kryczek I, et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol. 2005;54:369-377.
23. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
24. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388.
25. Stephens LA, Gray D, Anderton ST. CD4+ CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity. Procl Natl Acad USA. 2005;102:17418-17423.
26. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Canc. 2007;7:880-887.
27. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723-735.
28. Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142-1151.
29. Thornton AM, Donovan EE, Piccirillo CA, et al. Cutting Edge: IL-2 is critically required for the in vitro activation of CD4+ CD25+ T cell suppressor function. J Immunol. 2004;172: 6519-6523.
30. Yu A, Malek TR. Selective availability of IL-2 is a major determinant controlling the production of CD4+ CD25+ Foxp3+ T regulatory cells. J Immunol. 2006;177:5115-5121.
31. Rao BM, Driver I, Lauffenburger DA, et al. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry. 2005;44:10696-10701.
32. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A. 2003;55:61-70.
33. Maier LM, Anderson DE, De Jager PL, et al. Allelic variant in CTLA4 alters T cell phosphorylation patterns. Proc Natl Acad Sci USA. 2007;104:18607-18612.
34. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of Interleukin-2 with its alpha, beta, and gammac receptors. Science. 2005;310:1159-1163.
35. Stauber DJ, Debler EW, Horton PA, et al. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cyto-kine receptor. Procl Natl Acad Sci USA. 2006;103:2788-2793.
36. Cassell DJ, Choudhri S, Humphrey R, et al. Therapeutic enhancement of IL-2 through molecular design. Curr Pharm Des. 2002;8:2171-2183.
37. Shanafelt AB, Lin Y, Shanafelt MC, et al. A T-cell-selec-tive interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol. 2000;18: 1197-1202.
38. Collins L, Tsien WH, Seals J, et al. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc Natl Acad Sci USA. 1988;85:7709-7713.
39. Eckenberg R, Xu D, Moreau JL, et al. Analysis of human IL-2/IL-2 receptor beta chain interactions: monoclonal antibody H2-8 and new IL-2 mutants define the critical role of a helix-A of IL-2. Cytokine. 1997;9:488-498.
40. Buchli P, Ciardelli T. Structural and biologic properties of a human aspartic acid-126 interleukin-2 analog. Arch Biochem Biophys. 1993;307:411-415.
41. Liang SM, Thatcher DR, Liang CM, et al. Studies of structure-activity relationships of human interleukin-2. J Biol Chem. 1986;261:334-337.
42. Liparoto SF, Myszka DG, Wu Z, et al. Analysis of the role of the interleukin-2 receptor gamma chain in ligand binding. Biochemistry. 2002;41:2541-2551.
43. Bensinger SJ, Walsh PT, Zhang J, et al. Distinct IL-2 receptor signaling pattern in CD4+ CD25+ regulatory T cells. J Immunol. 2004;172:5287-5296.
44. Smith KA. The interleukin 2 receptor. Annu Rev Cell Biol. 1989;5:397-425.
45. Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22:3099-3108.
46. Saragovi H, Malek TR. Direct identification of the murine IL-2 receptor p55-p75 heterodimer in the absence of IL-2. J Immunol. 1988;141:476-482.
47. Goldstein B, Jones D, Kevrekidis IG, et al. Evidence for p55-p75 heterodimers in the absence of IL-2 from Scatchard plot analysis. Int Immunol. 1992;4:23-32.
48. Roessler E, Grant A, Ju G, et al. Cooperative interactions between the interleukin 2 receptor a and b chains alter the interleukin 2-binding affinity of the receptor subunits. Proc Natl Acad Sci U S A. 1994;91:3344-3347.
49. Fallon EM, Liparoto SF, Lee KJ, et al. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J Biol Chem. 2000;275:6790-6797.